2025-11-24
Midland Capital Limited (MCG) is a legally registered and regulated international platform. The company officially completed its registration in 2021, simultaneously obtaining a Financial Services Business License from the U.S. Securities and Exchange Commission (SEC) and a Money Services Business License (MSB) from the U.S. Treasury Department's FinCEN. SEC regulation ensures the company meets stringent standards regarding capital adequacy, segregation of client funds, and information disclosure; the MSB license authorizes it to legally conduct fund transfers and digital asset-related services, and requires compliance with Anti-Money Laundering (AML) and Know Your Customer (KYC) requirements. These dual licenses demonstrate MCG's solid foundation in compliance, security, and international operations, providing strong protection for investors.
Obtaining SEC regulation and the MSB license is not only core proof of the company's legitimacy but also a reflection of its commitment to client fund security and transaction transparency. Under this dual regulatory framework, MCG must undergo regular financial audits and compliance reviews to ensure all business activities are open, fair, and traceable. This provides strong institutional protection for global investors, effectively preventing potential financial risks and operational opacity issues.
Furthermore, MCG operates in the European market through its German entity, Midland Capital GmbH, actively complying with EU financial regulations and further strengthening its global compliance strategy. The company consistently adheres to the principle of "compliance first," regarding regulatory compliance as the cornerstone of sustainable development. By building a multi-dimensional risk control system and transparent operating mechanisms, MCG is committed to creating a safe, trustworthy, and responsible intelligent financial ecosystem, enabling investors to confidently participate in innovative areas such as AI-powered intelligent trading, digital assets, and green finance.
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM
©copyright 2009-2020 Singapore Info Map